The latest FDA approval was based on the results of the ADVANCE trial, which showed that five times as many adults with mild to moderate plaque psoriasis receiving oral Otezla 30 mg twice daily ...

Amgen maintains that Otezla remains the only approved oral systemic therapy with a broad indication and is “well positioned” to help the 4 million US patients with mild to moderate psoriasis ...

Dallas is an Otezla patient who has been compensated for his time. Courtesy of Amgen Inc. Plaque psoriasis is a fairly common autoimmune skin condition — as many as 6.7 million people in the US ...

For many people with mild psoriasis ... Some prescription oral medications to manage psoriasis include Rheumatrex (methotrexate), Otezla (apremilast), Soriatane (acitretin), and Sotyktu ...

For example, a study of apremilast (Otezla) in palmoplantar pustulosis ... a recent study of apremilast in patients with mild/moderate plaque psoriasis that had not responded to one or more ...

Topical therapies are relatively low-cost and usually the first approach in people with mild to moderate psoriasis ...

Several classification systems, all based on disease severity, have been created to guide treatment decisions in psoriasis. In the most widely used system, disease severity is scored according to ...

The psoriasis pipeline possesses some drugs in mid- and late-stage development to be approved in the near future. The emerging landscape holds a dive ...

"Based on the especially promising safety and efficacy results from patients with mild-to-moderate psoriasis in Cohort 2 of our Phase 1b clinical trial, we are confident that SFA-002 will ...

Generalized Pustular Psoriasis, Mild to Moderate Plaque Psoriasis, and Moderate to Severe Psoriasis. These reports include a comprehensive understanding of current treatment practices, emerging ...